Management of the risk of thromboembolic complications in oncology
Keywords:
cancer, cancer-associated thrombosis, risk factors, algoritmAbstract
Oncological disease is a hypercoagulable state with an associated increased risk of venous thromboembolism and is associated with high rates of recurrence and mortality. For those reasons, the prevention of cancer-associated thrombosis is of paramount importance. Knowledge of thromboembolic risk factors in oncology is absolutely necessary for the evaluation of the individual risk-benefit ratio of prophylaxis. The aim of this paper is to elucidate the risk factors of thromboembolic complications in cancer patients. In order to achieve the set aim, the medical scientifi c publications from the GoogleSearch database, PubMed, Z-library, NCIB, Medscape, Hinari, were searched for the keywords: „cancer-associated thrombosis”, „cancer”, „risk factor”. The information was systematized, highlighting the risk factors for thromboembolic complications
in patients with cancer.
References
1. IKEDA, S., KOGA, S., YAMAGATA, Y. et al. Comparison of the effects of endoxaban, an oral direct factor Xa inhibitor on venous thromboembolism between patients with and without cancer. Journal of Cardiology, 2018, nr. 72, p. 120-127. https://doi.org/10.1016/j.jjcc.2018.03.006
2. FALANGA, A., RUSSO, L., MILESI, V. et al. Mechanisms and risk factors of thrombosis in cancer. Critical Reviews in Oncology and Hematology, 2017, nr. 118, p. 79-83. https://doi.org/10.1016/j.critrevonc.2017.08.003
3. JARA-PALOMARES, L., OTERO, R., JIMENEZ, D. et al. Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism. PLoS One, 2018, vol. 13, nr. 3, e0194673. https://doi.org/10.1371/journal.pone.0194673
4. FALANGA, A., SCHIEPPATI, F., RUSSO, D. Cancer tissue procoagulable state of patients with cancer. Seminars in Thrombosis and Hemostasis, 2015, vol. 41, nr. 7, p. 756-764. https://doi.org/10.1055/s-0035-1564040
5. FALANGA, A., SCHIEPPATI, F., RUSSO, D. Mechanisms of thrombosis in cancer patients. Cancer Treatment Research, 2019, nr. 179, p. 11-36. https://doi.org/10.1007/978-3-030-20315-3_2
6. LIEBMAN, H., O'CONNELL, C. Incidental venous thromboembolic events in cancer patients: what we know in 2016. Thrombosis Research, 2016, vol. 140, nr. 1, p. 12-17. https://doi.org/10.1016/S0049-3848(16)30093-7
7. KRAVTSOV, P., KOTORKIN, S., MELNICOV, M. Clinical experience with the use of rivaroxaban in the treatment of cancer patients with venous thrombosis. Khirurgiia, 2018, nr. 1, p. 57-63. https://doi.org/10.17116/hirurgia2018157-63
8. ANTIĆ, D., MILIĆ, N., SRDJAN, N. et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. American Journal of Hematology, 2016, vol. 91, nr. 10, p. 1014-1019. https://doi.org/10.1002/ajh.24466
9. SILIȘTE, N., SĂMLESCU-FIEDLER, I., GURGHEAN, A. Boala tromboembolică venoasă la pacienții cu cancer. Revista Societății de Medicină Internă, 2016, p. 1-11.
10. HIRAIDE, M., SHIGA, T., MINOWAS, Y. et al. Identification of risk factors for venous thromboembolism in Thai hospitalized lymphoma patients. Journal of Cardiology, 2020, vol. 75, nr. 1, p. 110-114. https://doi.org/10.1016/j.jjcc.2019.06.013
11. FONT, C., FARRÚS, B., VIDAL, L. et al. Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients. Annals of Oncology, 2011, vol. 22, p. 2101. https://doi.org/10.1093/annonc/mdq720
12. HISADA, Y., GEDDINGS, J., BOULAFTALI, Y. et al. Tissue factor positive microvesicles activate platelets in vitro and in vivo and enhance thrombosis in mice. Thrombosis Research, 2016, vol. 140, nr. 1, p. 169-170. https://doi.org/10.1016/S0049-3848(16)30121-9
13. PEIPPO, M., KURKI, S., LASSIBO, R. Real-world features associated with cancer-related venous thromboembolic events. BMJ, 2020, nr. 3, p. 1-10.
14. TIMP, J., BRAEKKAN, S., CANNEGIETER, S. Epidemiology of cancer-associated venous thrombosis. Blood, 2013, vol. 122, nr. 10, p. 1712-1723. https://doi.org/10.1182/blood-2013-04-460121
15. COLOMBO, R., GALLIPOLI, P., CASTELLI, R. Thrombosis and hemostatic abnormalities in hematological malignancies. Clinical Lymphoma Myeloma and Leukemia, 2014, nr. 14, p. 441-450. https://doi.org/10.1016/j.clml.2014.05.003
16. CARUSO, V., CASTELNUOVO, A., MESCHEHGIESER, S. et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18018 patients and 1149 events. Blood, 2010, nr. 115, p. 5322-5328. https://doi.org/10.1182/blood-2010-01-258624
17. FALANGA, A., MARCHETTI, M., RUSSO, L. Venous thromboembolism in the hematologic malignancies. Current Opinion in Oncology, 2011, nr. 24, p. 702-710. https://doi.org/10.1097/CCO.0b013e3283592331
18. ФЁДОРОВ, А., ДМИТРИЕВ, В., ЛИПАЙ, Н. Венозные тромбозы у детей, подростков и молодых взрослых больных лимфомами: частота развития, характеристика, факторы риска и влияние на прогноз. Онкогематология, 2018, т. 13, № 2, с. 9-21.
19. ЛИПАЙ, Н., ФЁДОРОВ, А., ДМИТРИЕВ, В. Тромботические осложнения у детей с неходжкенскими лимфомами. Онкогематология, 2013, № 2, с. 41-46.
20. VISWESHWAR, N., JAGLAL, M., SOKOL, L. et al. Hematological Malignancies and Arterial Thromboembolism. Indian Journal of Hematology and Blood Transfusion, 2019, vol. 35, nr. 4, p. 611-624. https://doi.org/10.1007/s12288-019-01085-x
21. ВОРОБЬЁВ, А., МАКАЦАРИЯ, А. Тромбофилия, тромбозы и антитромботическая терапия у онкологических больных. Акушерство. Гинекология. Репродукция, 2014, т. 8, № 2, с. 139-148.
22. EICHINGER, S. Cancer associated thrombosis: risk factors and outcomes. Thrombosis Research, 2016, vol. 140, nr. 1, p. 12-17. https://doi.org/10.1016/S0049-3848(16)30092-5
23. KUNAWUTTINANKORN, W., TANYASALNSOOK, K., ROJNUCKARIN, P. Incidence and risk factors for venous thromboembolism in Thai hospitalized lymphoma patients. Pharmaceutical Sciences Asia, 2018, vol. 45, nr. 2, p. 114-122. https://doi.org/10.29090/psa.2018.02.114
24. ROOPKUMAR, J., KHORANA, A. Risk of thrombosis in cancer: clinical factors and role of primary prophylaxis. Cancer Treatment Research, 2019, nr. 179, p. 55-68. https://doi.org/10.1007/978-3-030-20315-3_4
25. SCOTTÉ, F., LEROY, P., CHASTENET, M. et al. Tratamentul și prevenirea trombozei asociate cancerului la pacienții fragili: management adaptat. 2019, vol. 11, nr. 1, p. 48. https://doi.org/10.3390/cancers11010048
26. JOSEPHS, S., ICHIM, T., PRINCE, S. et al. Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. Journal of Translational Medicine, 2018, vol. 16, p. 242. https://doi.org/10.1186/s12967-018-1611-7
27. YOUNG, A., CHAPMAN, O., CONNOR, C. et al. Thrombosis and cancer. Nature Reviews Clinical Oncology, 2012, vol. 9, p. 437-449. https://doi.org/10.1038/nrclinonc.2012.106
28. RIONDINO, S., FERRONI, P., ZANZOTTO, F. Predicting VTE in cancer patients: candidate biomarkers and risk assessment models. Cancers, 2019, vol. 11, nr. 1, p. 95. https://doi.org/10.3390/cancers11010095
29. MAHAJAN, A., WUN, T., CHEW, H. et al. Lymphoma and venous thromboembolism: influence on mortality. Thromboembolism, 2014, nr. 133, p. 23-28. https://doi.org/10.1016/S0049-3848(14)50004-7
30. HOHAUS, S., BARTOLOMEI, F., CUCCARO, A. et al. Venous thromboembolism in lymphoma: risk stratification and antithrombotic prophylaxis. Cancers, 2020, vol. 12, nr. 5, p. 1291. https://doi.org/10.3390/cancers12051291
31. HOHAUS, S., TISI, M., BARTOLOMEI, F. et al. Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization. Blood Cancer Journal, 2018, vol. 8, nr. 6, p. 54. https://doi.org/10.1038/s41408-018-0096-1
32. FRANCHINI, M. Thromboembolic risk in hematological malignancies. Clinical Chemistry and Laboratory Medicine, 2014, vol. 53, nr. 8, p. 1139-1147. https://doi.org/10.1515/cclm-2014-1010
33. EASAW, J., MCCALL, S., AZIM, A. Clot Assist: A program to treat cancer-associated thrombosis in an outpatient pharmacy setting. Journal of Oncology Pharmacy Practice, 2019, vol. 25, nr. 4, p. 818-823. https://doi.org/10.1177/1078155218760704
34. ABUFARA, A., MA'KOSEH, M., MAVISOUR, A. et al. High incidence of venous thromboembolic events in patients with diffuse large B cell lymphoma. Annals of Oncology, 2019, vol. 30, nr. 5. https://doi.org/10.1093/annonc/mdz265.022
35. COHEN, A., KATHOLING, A., RIETBROCK, S. et al. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer: a population based cohort study. Thrombosis and Haemostasis, 2016, nr. 117, p. 57-65. https://doi.org/10.1160/TH15-08-0686
36. RAZAK, A., JONES, G., BHANDARI, M. et al. Cancer-associated thrombosis: an overview of mechanisms, risk factors and treatment. Cancers, 2018, vol. 10, nr. 10, E380. https://doi.org/10.3390/cancers10100380
37. KEY, N., KHORANA, A., KUDERER, N. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2019. https://doi.org/10.1200/JOP.19.00368
38. PATEL, H., KHORANA, A. Anticoagulation in cancer patients: a summary of pitfalls to avoid. Current Oncology Reports, 2019, vol. 21, nr. 2, p. 18. https://doi.org/10.1007/s11912-019-0767-5
39. SANFILIPPO, K. et al. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma. Thrombosis Research, 2016, nr. 143, p. 86-90. https://doi.org/10.1016/j.thromres.2016.05.008
40. FARGE, D., FRERE, C., CONNORS, J.M. et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncology, 2019, vol. 20, p. e566. https://doi.org/10.1016/S1470-2045(19)30750-8
41. GULRAYZ, A., GULRAYZ, N., KATHRIN, H. et al. Validation of the Khorana Score to assess venous thromboembolism and its association with mortality in cancer patients: a retrospective community-based observational experience. Cureus, 2020, vol. 12, nr. 4, e7883.
42. AHMED, G., HALL, K.T., WEISSMANN, L.B. Validation of the Khorana Score to assess venous thromboembolism and its association with mortality. Blood, 2019, vol. 134, p. 2119. https://doi.org/10.1182/blood-2019-124240
43. KUDERER, N.M., CULAKOVA, E., LYMAN, G.H. et al. A validated risk score for venous thromboembolism is predictive of cancer progression and mortality. The Oncologist, 2016, vol. 21, p. 861-867. https://doi.org/10.1634/theoncologist.2015-0361
44. DUTIA, M., WHITE, R.H., WUN, T. Risk assessment models for cancer-associated venous thromboembolism. Cancer, 2012, vol. 118, p. 3468. https://doi.org/10.1002/cncr.26597
45. LUND, J., OSTGARD, L. et al. Incidence, determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark. Thrombosis Research, 2015, vol. 136, nr. 5, p. 917-923. https://doi.org/10.1016/j.thromres.2015.09.001
46. GANGARAJU, R., CHEN, Y., HAGEMAN, L. et al. Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation. Cancer, 2019, vol. 125, nr. 24, p. 4498-4508. https://doi.org/10.1002/cncr.32488
47. МАДЕРА, А. Риски и шансы: неопределённость, прогнозирование и оценка. Краснодар, 2013. 448 с.
48. HOHAM, S., BARTOLOMEI, F., CUCCARO, A. et al. Venous thromboembolism in lymphoma: risk stratification and antithrombotic prophylaxis. Cancers, 2020, vol. 12, nr. 5, p. 1291. https://doi.org/10.3390/cancers12051291
49. CONNORS, J.M. Prophylaxis against venous thromboembolism in ambulatory patients with cancer. New England Journal of Medicine, 2014, vol. 370, p. 2515. https://doi.org/10.1056/NEJMra1401468
50. MUÑOZ MARTÍN, A.J., ORTEGA, I., FONT, C. et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. British Journal of Cancer, 2018, vol. 118, p. 1056. https://doi.org/10.1038/s41416-018-0027-8
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
